# Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

> **NCT03500094** · PHASE3 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Migalastat HCl 150 mg

## Key facts

- **NCT ID:** NCT03500094
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-27
- **Primary completion:** 2021-02-02
- **Final completion:** 2021-02-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03500094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03500094, "Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03500094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*